• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Alerts
CMECNE

SMFM Recommendations: FGR Diagnosis and Management

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Discuss the definitions associated with fetal growth restriction (FGR)
2. Describe the fetal assessment options when a patient has been diagnosed with FGR

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from through , participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

SUMMARY:

SMFM has released guidance on fetal growth restriction (FGR), an evidence-based document that provides a standardized approach to diagnosis and management. The document emphasizes the importance of FGR as a significant pregnancy complication that

…occurs in up to 10% of pregnancies and is second to premature birth as a cause of infant morbidity and mortality. In addition to its significant perinatal impact, FGR also has an impact on long-term health outcomes

  • Diagnosis of FGR and Definitions
  • FGR Workup
  • Fetal Assessment
  • FGR Prevention and Treatment
  • FGR Delivery Timing

Diagnosis of FGR and Definitions

ACOG FGR Definition

  • FGR: EFW <10th percentile for gestational age
  • Small for gestational age (SGA): Newborn birthweight <10th percentile for gestational age

SMFM FGR Definition

  • SMFM supports the above ACOG definitions
  • SMFM also includes AC<10th percentile for gestational age for FGR diagnosis
    • Screening performance similar between EFW and AC (see ‘Related ObG Topics’ below)

Note: The term ‘IUGR’ should no longer be used | SMFM document, based on more recent evidence, does not consider symmetric vs asymmetric FGR to be helpful in determining prognosis

Early onset FGR: <32 weeks

  • More severe disease course and more likely to be associated with
    • Placental insufficiency
    • Hypertensive disorders
    • Genetic disorders
    • Maternal hypertension
    • Doppler abnormalities

Late onset of FGR ≥32 weeks

  • Accounts for 70-80% cases
    • Generally, milder clinical course and without flow abnormalities

Severe FGR

  • EFW <3rd percentile
  • Consistent with a more severe form of FGR

KEY POINTS:

FGR Workup

  • Detailed ultrasound
    • Strong association with fetal anomalies and/or chromosomal disorders (20%)
    • Detailed ultrasound CPT code: 76811
  • Genetics and fetal diagnostic testing: Chromosomal Microarray Analysis (see ‘Related ObG Topics’ below) is indicated for the following
    • FGR <32 weeks
    • FGR and polyhdramnios and/or fetal malformation are detected regardless of gestational age
  • Viral work-up
    • CMV testing
      • Associated with isolated FGR | However, routine testing not recommended due to low CMV incidence
      • Offer CMV (PCR) if patient undergoing amniocentesis
    • Toxoplasmosis, rubella, or herpes and isolated FGR
      • Routine screening is not recommended unless other risk factors are identified

Fetal Assessment

NST (Cardiotocography [CTG])

  • Weekly NSTs after viability
  • Increase frequency if warranted based on Doppler abnormalities or other clinical indications (e.g. comorbidities or risk factors)
  • SMFM addresses BPP in the statement and finds that “further studies are required to prove usefulness of BPP”

Umbilical Artery (UA) Doppler Measurement

  • Normal flow measurements
    • UA Dopplers every 1 to 2 weeks
  • Abnormal end diastolic velocity (EDV)
    • Decreased EDV (flow ratios >95th percentile) or FGR <3rd percentile: Weekly Dopplers
    • Absent end diastolic velocity (AEDV): 2 to 3 times/week
    • Reversed end diastolic velocity (REDV)
      • Hospitalize
      • Administer antenatal corticosteroids
      • Perform NST 1 to 2 times/day | Low threshold for delivery depending on clinical scenario

Note: SMFM recommends against routine use of ductus venosus dopplers, middle cerebral artery dopplers, or uterine artery Doppler studies in early or late onset FGR | These studies have not been found to lead to improved accuracy over umbilical artery dopplers

FGR Prevention and Treatment

Prevention

  • Due to lack of evidence, SMFM recommends against the use of the following for prevention of FGR
    • Prenatal aspirin (conflicting data including negative result in ASPRE trial)
    • LMWH

Treatment

  • SMFM recommends against the use for treatment of FGR
    • Sildenafil
    • Activity restriction

FGR Delivery

Timing

  • With oligohydramnios: 34w0d to 37w6d
  • Normal UA Doppler and EFW 3 to 10th percentile: 38 to 39 weeks
  • EFW <3rd percentile (severe FGR): 37 weeks
  • Decreased UA flow (S/D, RI, or PI > 95 percentile): 37 weeks
  • AEDV: 33 to 34 weeks
  • REDV: 30 to 32 weeks

Mode of Delivery

  • Cesarean delivery
    • No strict recommendation for cesarean delivery based on FGR alone
    • Reserve for usual fetal and maternal indications
  • Mode of delivery for most cases of severe FGR with umbilical artery changes (AEDV or REDV): Cesarean delivery for fetal indication
  • Mode of delivery should be determined on a case-by-case basis, taking in to account clinical presentation and maternal preferences

FGR and Preterm

  • Administer corticosteroids and magnesium sulfate as per current guidelines

Learn More – Primary Sources:

SMFM Consult Series 52: Diagnosis and Management of Fetal Growth Restriction

ACOG Practice Advisory: Updated Guidance Regarding Fetal Growth Restriction

Take a post-test and get CME credits

TAKE THE POST TEST

Get Guideline Notifications direct to your phone with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Alerts Posts
Next >

Related ObG Topics:

Fetal Growth Restriction: Definition, Evaluation and Management
Antenatal Corticosteroids – When to Administer?
ACOG SMFM Recommendations: When to Deliver Medically Complicated Pregnancies
Can Abdominal Circumference Alone Be Used to Predict SGA or LGA Newborns?
The Use of Microarrays in the Prenatal and Postnatal Setting – Current Professional Guidelines
ASPRE Trial: A Combined Risk Algorithm and Use of Aspirin to Prevent Preterm Preeclampsia

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site